Page 4 - Laurus Labs

Laurus Labs hits fresh record high on expectation of strong earnings

Analysts believe Laurus is well poised to follow the success story of some leading CDMO players backed by strong chemistry and integrated model

Laurus Labs trades higher for fourth straight day; stock hits record high

The stock has outperformed the market in past four months. It has rallied 171 per cent since June on the back of strong quarterly earnings.

GMM Pfaudler, Laurus Labs, Birlasoft: 13 BSE500 stocks that doubled in 2020

Going ahead, most analysts expect the mid-and small-cap segments to continue doing well as compared to their large-cap peers, which they feel are now fairly valued

Laurus Labs in focus, zooms over 15%; stock hits all-time high

For the April-June, 2020 quarter, Laurus Labs posted consolidated revenue of Rs 974 crore, up 77 per cent year-on-year (YoY)

RIL hits Rs 2000 mark; Muthoot Finance, Laurus Labs hit record high

RIL hit a fresh record high of Rs 2,000 mark, up 1.4 per cent in intra-day trade today.

Aarti Drugs to Tata Comm: Earnings rise for 15 firms in Covid-19 economy

These companies reported an increase in revenue and/or profit before tax for the March quarter

Nifty likely to clear the hurdle of 10,850 very soon: Sameet Chavan

The index may see some profit-booking once it reaches the 78.6 per cent retracement zone of the entire fall i.e. 11,000-11,200 levels

Defensive traders should refrain from aggressive bets on Nifty: Nilesh Jain

The overall fall in volatility is hinting at no major move in the short-term

Laurus Labs under pressure, plunges 10% after multiple block deals

Till 12:44 pm, a combined 34.4 million equity shares, representing 32.2 per cent of total equity of Laurus Labs, changed hands on the BSE and NSE.

Pharma shares rally; Alembic, Sun Pharma, Laurus Labs hit 52-wk highs

Strides Pharma Science, Alkem Laboratories, Ajanta Pharma, Lupin, Ipca Laboratories, Jubilant Life Sciences and FDC were up in the range of 5 per cent to 10 per cent on the BSE

Laurus Labs surges 50% in one month on growth prospects in US market

The stock hit a 52-week high of Rs 494, up 9 per cent on the BSE on Wednesday, surging 20 per cent in past two trading days on expectation of strong growth prospects in United States.

Patent for Pharmacyclic's cancer drug revoked on challenge by Laurus Labs

Patent Office rules that the drug isn't an improvement over other formulations in the same space, hence not eligible to enjoy a patent

Laurus Labs launches generic Lyrica in US to treat neuropathic conditions

Market size in the US for the API was about $5,497 million in FY19; firm says generic launch is one of its largest this year

Laurus gets USFDA nod for drug that treats malaria, auto-immune disease

Medicine is a therapeutic equivalent of Plaquenil tablets of Concordia Pharma of US

Laurus Labs hits record low on disappointing Q1 results

The stock slipped 8% to Rs 430 on the BSE in intra-day trade after the company reported 57% year-on-year decline in net profit at Rs 166 million in June quarter.

Laurus Labs gets USFDA nod for Visakhapatnam unit

The firm is one of the leading manufacturers of APIs for anti-retroviral (ARV), Hepatitis C, and Oncology

Laurus Labs Q1 net up 51% at Rs 39 cr

Total revenue grew 16.7% to Rs 478.4 cr

Laurus Labs lists at Rs 490, 14% premium against its issue price

On the NSE, the stock listed at Rs 489.90 and gained as much as Rs 498

Laurus Lab set for stock trading debut from Monday

The IPO, which opened to public subscription on December 6-8, was subscribed 4.54 times at a price band of Rs 426-428 per share

Laurus Labs' IPO sails through, subscribed 4.5 times

The Rs 1,332-cr IPO received bids for over 9.87 crore shares as against the total issue size of over 2.19 crore scrips